Product logins

Find logins to all Clarivate products below.


Major Depressive Disorder (DSM-V) – Epidemiology – Epidemiology – Major Depressive Disorder (DSM V) – Mature Markets

Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report the prevalence of MDD (DSM-V) for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s MDD (DSM-V) forecast will answer the following questions:

  • Of all people with MDD (DSM-V), how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with MDD (DSM-V), how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDD (DSM-V) over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology forecasts the following MDD (DSM-V) patient populations:

  • Total lifetime prevalent cases.
  • Total 12-month prevalent cases.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Landscape & Forecast – Disease Landscape & Forecast (G7)
The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of generic drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Ocular Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Schizophrenia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Schizophrenia (US)
Schizophrenia is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…